Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Carcinoma, Non-Small-Cell Lung 58Breast Neoplasms 43Prostatic Neoplasms 32Lung Neoplasms 29Multiple Myeloma 23Neoplasms 22Parkinson Disease 4, Autosomal Dominant Lewy Body 17Ovarian Neoplasms 17Colorectal Neoplasms 17Neoplasm Metastasis 16Leukemia, Lymphocytic, Chronic, B-Cell 16Carcinoma, Renal Cell 14Pancreatic Neoplasms 13Endometrial Neoplasms 12Small Cell Lung Carcinoma 11Urinary Bladder Neoplasms 10Stomach Neoplasms 10Squamous Cell Carcinoma of Head and Neck 10Myasthenia Gravis 9Lymphoma, Follicular 9Leukemia, Myeloid, Acute 9Fallopian Tube Neoplasms 9Non-Muscle Invasive Bladder Neoplasms 8Colonic Neoplasms 8Burkitt Lymphoma 7Recurrence 6Lymphoma, Mantle-Cell 6Esophageal Neoplasms 6Adenocarcinoma 6Triple Negative Breast Neoplasms 5

Interventions

palbociclib 1Letrozole 1Fulvestrant 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Breast Neoplasm Female × 30 days × Clear all
NCT05417516 2026-05-22

A Randomized Trial of Five Fraction Partial Breast Irradiation (RAPID2)

Ontario Clinical Oncology Group (OCOG)

Phase 3 Recruiting
910 enrolled
Breast

Breast Neoplasm Female

NCT03425838 2026-05-20

Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer

Borstkanker Onderzoek Groep

Phase 3 Active not recruiting
1,050 enrolled
Breast

Breast Neoplasm Female

Data powered by HemOnc (CC BY 4.0) Colophon âš¡